Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma

Fig. 1

The prediction ability of serum inflammation indexes to distinguish responders and non-responders (showing the serum inflammation indexes with relatively good prediction ability). A NLR at baseline; B LMR at baseline; C PLR at baseline; D SII at baseline; E LMR at post treatment of second period; F LMR at post treatment of third period; G PLR at post treatment of third period; H SII at post treatment of second period; I Predictive model of combining serum biomarkers; J Predictive model of combining NLR and SII at baseline; K Predictive model of combining LMR and SII at baseline; L Predictive model of combining PLR and SII at baseline

Back to article page